{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:45:38Z","timestamp":1762033538244,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Celator Pharma"},{"DOI":"10.13039\/501100001318","name":"University of the West of England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012141","name":"University Hospitals Bristol NHS Foundation Trust","doi-asserted-by":"crossref","award":["07\/H1107\/181"],"award-info":[{"award-number":["07\/H1107\/181"]}],"id":[{"id":"10.13039\/100012141","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.leukres.2018.08.007","type":"journal-article","created":{"date-parts":[[2018,8,11]],"date-time":"2018-08-11T16:05:06Z","timestamp":1534003506000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6210-8653","authenticated-orcid":false,"given":"Elizabeth","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Heywood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Bone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7002-1320","authenticated-orcid":false,"given":"Darren","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vyv","family":"Salisbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"January (11)","key":"10.1016\/j.leukres.2018.08.007_bib0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"Gandhi","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2018.08.007_bib0010","first-page":"1079","article-title":"Regulation of 1-beta-D-arabinofuranosylcytosine 5\u2019-triphosphate accumulation in human leukemia cells by deoxycytidine 5\u2019-triphosphate","volume":"46","author":"Liliemark","year":"1986","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.leukres.2018.08.007_bib0015","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1016\/S0021-9258(18)60539-3","article-title":"Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase","volume":"264","author":"Datta","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.leukres.2018.08.007_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.leukres.2018.08.007_bib0025","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk. Res."},{"issue":"21","key":"10.1016\/j.leukres.2018.08.007_bib0030","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2018.08.007_bib0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"121(2)","key":"10.1016\/j.leukres.2018.08.007_bib0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.28974","article-title":"Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML","volume":"15","author":"Cortes","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2018.08.007_bib0045","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","article-title":"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia","volume":"36","author":"Feldman","year":"2012","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2018.08.007_bib0050","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","article-title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","volume":"9","author":"Kim","year":"2011","journal-title":"Exp. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2018.08.007_bib0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/17474086.2017.1369400","article-title":"CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?","volume":"10","author":"Brunetti","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.leukres.2018.08.007_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.12.002","article-title":"CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation","volume":"53","author":"Gordon","year":"2017","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2018.08.007_bib0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.leukres.2013.02.012","article-title":"A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines","volume":"37","author":"Anderson","year":"2013","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.leukres.2018.08.007_bib0070","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.bcp.2009.03.011","article-title":"Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase\/cytosolic 5\u2019-nucleotidase II expression ratio in primary acute myeloid leukemia cells","volume":"77","author":"Yamauchi","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"14","key":"10.1016\/j.leukres.2018.08.007_bib0075","doi-asserted-by":"crossref","first-page":"23073","DOI":"10.18632\/oncotarget.14981","article-title":"Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome","volume":"8","author":"Macanas-Pirard","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.leukres.2018.08.007_bib0080","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1373\/clinchem.2010.145581","article-title":"A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia","volume":"56","author":"Alloush","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.leukres.2018.08.007_bib0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.08.007_bib0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.2910260208","article-title":"Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)","volume":"2","author":"Tsuchiya","year":"1980","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2018.08.007_bib0095","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2013.08.063","article-title":"Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4)","volume":"86","author":"Wang","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.leukres.2018.08.007_bib0100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1159\/000239026","article-title":"Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells","volume":"38","author":"Riva","year":"1992","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.leukres.2018.08.007_bib0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood.V62.4.709.709","article-title":"Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications","volume":"62","author":"Koeffler","year":"1983","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.leukres.2018.08.007_bib0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2011.12.017","article-title":"Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity","volume":"318","author":"She","year":"2012","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.leukres.2018.08.007_bib0115","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-07-5528","article-title":"Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells","volume":"68","author":"Cai","year":"2008","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.leukres.2018.08.007_bib0120","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","article-title":"Potential mechanisms of resistance to cytarabine in AML patients","volume":"26","author":"Galmarini","year":"2002","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2018.08.007_bib0125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jcp.22045","article-title":"Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer","volume":"223","author":"Santini","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.leukres.2018.08.007_bib0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/sj.leu.2403582","article-title":"Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells","volume":"19","author":"Molina-Arcas","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2018.08.007_bib0135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0028-3908(97)00136-6","article-title":"Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells","volume":"36","author":"Boleti","year":"1997","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.leukres.2018.08.007_bib0140","first-page":"3005","article-title":"Saturation of 1-beta-D-arabinofuranosylcytosine 5\u2019-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy","volume":"47","author":"Plunkett","year":"1987","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2018.08.007_bib0145","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/0008-5472.CAN-03-2456","article-title":"The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines","volume":"64","author":"Ge","year":"2004","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2018.08.007_bib0150","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1096\/fj.01-0794fje","article-title":"Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts","volume":"16","author":"Grazide","year":"2002","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.leukres.2018.08.007_bib0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0006-2952(02)01181-4","article-title":"Inhibition of mitochondrial permeability transition and release of cytochrome c by anti-apoptotic nucleoside analogues","volume":"64","author":"Xue","year":"2002","journal-title":"Biochem. Pharmacol."},{"issue":"28","key":"10.1016\/j.leukres.2018.08.007_bib0160","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1038\/sj.onc.1206486","article-title":"Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation","volume":"22","author":"Sreenivasan","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.leukres.2018.08.007_bib0165","first-page":"1657","article-title":"Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro","volume":"34","author":"Yamauchi","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.leukres.2018.08.007_bib0170","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.leu.2402179","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR\/ABL inhibition, cytotoxic drugs, and \u03b3-irradiation","volume":"15","author":"Damiano","year":"2001","journal-title":"Leukemia"},{"issue":"1-2","key":"10.1016\/j.leukres.2018.08.007_bib0175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11010-011-0730-8","article-title":"A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells","volume":"351","author":"Peng","year":"2011","journal-title":"Mol. Cell. Biochem."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T05:17:49Z","timestamp":1717219069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618301851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":35,"alternative-id":["S0145212618301851"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.08.007","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}